- Recruiting
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM
Updated: Feb 5
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.
Sponsor
Hackensack Meridian Health
ClinicalTrials.gov Identifier: NCT05199311
Official Title: A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma
First Posted : January 20, 2022
Click here for details on Clinicaltrials.gov
Drug: Carfilzomib
Drug: Iberdomide
Drug: Oral Dexamethasone
Location
United States, New Jersey